6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
Disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Malignant	JJ	malignant	malignant	malign	N	B-AdverseReaction
Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Gallbladder	NNP	gallbladder	gallbladder	gallbladd	N	B-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypertriglyceridemia	NNP	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
four	CD	four	four	four	N	O
prospective	JJ	prospective	prospective	prospect	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
the	DT	the	the	the	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
muscle	JJ	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
neck	RB	neck	neck	neck	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Pfizer	NNP	pfizer	pfizer	pfizer	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
438	CD	438	438	438	N	O
-	:	-	-	-	N	O
1985	CD	1985	1985	1985	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
conjugated	JJ	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
four	CD	four	four	four	N	O
Phase	NN	phase	phase	phase	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
duration	NN	duration	duration	durat	N	O
and	CC	and	and	and	N	O
enrolling	VBG	enrolling	enrolling	enrol	N	O
6	CD	6	6	6	N	O
,	,	,	,	,	N	O
210	CD	210	210	210	N	O
postmenopausal	NN	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
age	NN	age	age	age	N	O
40	CD	40	40	40	N	O
to	TO	to	to	to	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
224	CD	224	224	224	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
069	CD	069	069	069	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
received	VBD	received	received	receiv	N	O
calcium	NN	calcium	calcium	calcium	Y	O
(	(	(	(	(	N	O
600	CD	600	600	600	N	O
-	:	-	-	-	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
vitamin	$	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
(	(	(	(	(	N	O
200	CD	200	200	200	N	O
-	:	-	-	-	N	O
400	CD	400	400	400	N	O
IU	NNP	iu	iu	iu	N	O
)	)	)	)	)	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
women	NNS	women	woman	women	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
received	VBD	received	received	receiv	N	O
no	DT	no	no	no	N	O
calcium	NN	calcium	calcium	calcium	Y	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
as	IN	as	a	as	N	O
part	NN	part	part	part	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
protocol	NN	protocol	protocol	protocol	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
cause	NN	cause	cause	caus	N	O
mortality	NN	mortality	mortality	mortal	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	B-Negation
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
4.8%	CD	4.8%	4.8%	4.8%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
withdrew	VBP	withdrew	withdrew	withdrew	N	O
from	IN	from	from	from	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
7.5%	CD	7.5%	7.5%	7.5%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
10.0%	CD	10.0%	10.0%	10.0%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
hot	JJ	hot	hot	hot	N	B-AdverseReaction
flush	NN	flush	flush	flush	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
observed	JJ	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
Incidence	NNP	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
More	JJR	more	more	more	N	O
Common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Group	NNP	group	group	group	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1224	CD	1224	1224	1224	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1069	CD	1069	1069	1069	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
100	CD	100	100	100	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
58	CD	58	58	58	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
96	CD	96	96	96	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
57	CD	57	57	57	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
84	CD	84	84	84	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
81	CD	81	81	81	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
58	CD	58	58	58	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
110	CD	110	110	110	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Neck	NNP	neck	neck	neck	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
62	CD	62	62	62	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
65	CD	65	65	65	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
80	CD	80	80	80	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
61	CD	61	61	61	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Venous	JJ	venous	venous	venou	N	O
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
reporting	NN	reporting	reporting	report	N	O
rates	NNS	rates	rate	rate	N	O
for	IN	for	for	for	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
(	(	(	(	(	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
low	JJ	low	low	low	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	B-Negation
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
and	CC	and	and	and	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
low	JJ	low	low	low	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
conclude	VB	conclude	conclude	conclud	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
different	JJ	different	different	differ	N	O
from	IN	from	from	from	N	O
that	DT	that	that	that	N	O
seen	VBN	seen	seen	seen	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
therapies	NNS	therapies	therapy	therapi	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ENDOMETRIAL	NNP	endometrial	endometrial	endometri	N	B-AdverseReaction
CANCER	NNP	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
CARDIOVASCULAR	NNP	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
DISORDERS	NNP	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
PROBABLE	NNP	probable	probable	probabl	N	B-Factor
DEMENTIA	NNP	dementia	dementia	dementia	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ENDOMETRIAL	NNP	endometrial	endometrial	endometri	N	B-AdverseReaction
CANCER	NNP	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
CARDIOVASCULAR	NNP	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
DISORDERS	NNP	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
PROBABLE	NNP	probable	probable	probabl	N	B-Factor
DEMENTIA	NNP	dementia	dementia	dementia	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Women	NNP	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
additional	JJ	additional	additional	addit	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
[	MD	[	[	[	N	O
see	VB	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	RB	)]	)]	)]	N	O
\n	NNP	\n	\n	\n	N	O
There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
woman	NN	woman	woman	woman	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
uterus	NN	uterus	uterus	uteru	N	O
who	WP	who	who	who	N	O
uses	VBZ	uses	us	use	N	O
unopposed	JJ	unopposed	unopposed	unoppos	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	B-DrugClass
.	.	.	.	.	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	B-Factor
the	DT	the	the	the	N	I-Factor
risk	NN	risk	risk	risk	N	I-Factor
of	IN	of	of	of	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
hyperplasia	NN	hyperplasia	hyperplasia	hyperplasia	Y	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
precursor	NN	precursor	precursor	precursor	N	O
to	TO	to	to	to	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

Adequate	NNP	adequate	adequate	adequ	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
measures	NNS	measures	measure	measur	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
directed	VBD	directed	directed	direct	N	O
or	CC	or	or	or	N	O
random	JJ	random	random	random	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	O
sampling	NN	sampling	sampling	sampl	N	O
when	WRB	when	when	when	N	O
indicated	VBN	indicated	indicated	indic	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
undertaken	VBN	undertaken	undertaken	undertaken	N	O
to	TO	to	to	to	N	O
rule	VB	rule	rule	rule	N	O
out	RP	out	out	out	N	O
malignancy	NN	malignancy	malignancy	malign	N	O
in	IN	in	in	in	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
undiagnosed	JJ	undiagnosed	undiagnosed	undiagnos	N	O
persistent	NN	persistent	persistent	persist	N	O
or	CC	or	or	or	N	O
recurring	VBG	recurring	recurring	recur	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
genital	JJ	genital	genital	genit	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NNP	)]	)]	)]	N	O
\n	NNP	\n	\n	\n	N	O
Estrogen	NNP	estrogen	estrogen	estrogen	Y	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
prevention	NN	prevention	prevention	prevent	Y	O
of	IN	of	of	of	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
or	CC	or	or	or	N	O
dementia	NN	dementia	dementia	dementia	Y	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
\n	VBD	\n	\n	\n	N	O
The	DT	the	the	the	N	O
Women	NNP	women	woman	women	N	O
's	POS	's	's	's	N	O
Health	NNP	health	health	health	N	O
Initiative	NNP	initiative	initiative	initi	N	O
(	(	(	(	(	N	O
WHI	NNP	whi	whi	whi	N	O
)	)	)	)	)	N	O
estrogen	SYM	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
substudy	NN	substudy	substudy	substudi	N	O
reported	VBD	reported	reported	report	N	O
increased	JJ	increased	increased	increas	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
and	CC	and	and	and	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
DVT	NNP	dvt	dvt	dvt	Y	B-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
7.1	CD	7.1	7.1	7.1	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
daily	JJ	daily	daily	daili	N	O
oral	JJ	oral	oral	oral	N	B-DrugClass
conjugated	VBN	conjugated	conjugated	conjug	N	I-DrugClass
estrogens	NNS	estrogens	estrogen	estrogen	N	I-DrugClass
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
,	,	,	,	,	N	O
relative	JJ	relative	relative	rel	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
\n	VBD	\n	\n	\n	N	O
The	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
Memory	NNP	memory	memory	memori	N	O
Study	NNP	study	study	studi	N	O
(	(	(	(	(	N	O
WHIMS	NNP	whims	whim	whim	N	O
)	)	)	)	)	N	O
estrogen	SYM	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
ancillary	JJ	ancillary	ancillary	ancillari	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
WHI	NNP	whi	whi	whi	N	O
reported	VBD	reported	reported	report	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
probable	JJ	probable	probable	probabl	N	O
dementia	NN	dementia	dementia	dementia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
during	IN	during	during	dure	N	O
5.2	CD	5.2	5.2	5.2	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
daily	JJ	daily	daily	daili	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	B-DrugClass
estrogens	NNS	estrogens	estrogen	estrogen	N	I-DrugClass
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
,	,	,	,	,	N	O
relative	JJ	relative	relative	rel	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
whether	IN	whether	whether	whether	N	O
this	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
applies	VBZ	applies	applies	appli	N	O
to	TO	to	to	to	N	O
younger	VB	younger	younger	younger	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
\n	NN	\n	\n	\n	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
comparable	JJ	comparable	comparable	compar	N	O
data	NNS	data	data	data	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
risks	NNS	risks	risk	risk	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
assumed	VBN	assumed	assumed	assum	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
conjugated	JJ	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
dosage	NN	dosage	dosage	dosag	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
.	.	.	.	.	N	O

Estrogens	NNS	estrogens	estrogen	estrogen	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
lowest	JJS	lowest	lowest	lowest	N	O
effective	JJ	effective	effective	effect	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
shortest	JJS	shortest	shortest	shortest	N	O
duration	NN	duration	duration	durat	N	O
consistent	NN	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
treatment	NN	treatment	treatment	treatment	N	O
goals	NNS	goals	goal	goal	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
individual	JJ	individual	individual	individu	N	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ENDOMETRIAL	NNP	endometrial	endometrial	endometri	N	B-AdverseReaction
CANCER	NNP	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
CARDIOVASCULAR	NNP	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
DISORDERS	NNP	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
PROBABLE	NNP	probable	probable	probabl	N	B-Factor
DEMENTIA	NNP	dementia	dementia	dementia	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
additional	JJ	additional	additional	addit	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
woman	NN	woman	woman	woman	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
uterus	NN	uterus	uterus	uteru	N	O
who	WP	who	who	who	N	O
uses	VBZ	uses	us	use	N	O
unopposed	JJ	unopposed	unopposed	unoppos	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	B-DrugClass
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Estrogen	NNP	estrogen	estrogen	estrogen	Y	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
prevention	NN	prevention	prevention	prevent	Y	O
of	IN	of	of	of	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
or	CC	or	or	or	N	O
dementia	NN	dementia	dementia	dementia	Y	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
The	DT	the	the	the	N	O
Women	NNP	women	woman	women	N	O
's	POS	's	's	's	N	O
Health	NNP	health	health	health	N	O
Initiative	NNP	initiative	initiative	initi	N	O
(	(	(	(	(	N	O
WHI	NNP	whi	whi	whi	N	O
)	)	)	)	)	N	O
estrogen	SYM	estrogen	estrogen	estrogen	Y	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
substudy	NN	substudy	substudy	substudi	N	O
reported	VBD	reported	reported	report	N	O
increased	JJ	increased	increased	increas	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
and	CC	and	and	and	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
DVT	NNP	dvt	dvt	dvt	Y	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
The	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
Memory	NNP	memory	memory	memori	N	O
Study	NNP	study	study	studi	N	O
(	(	(	(	(	N	O
WHIMS	NNP	whims	whim	whim	N	O
)	)	)	)	)	N	O
estrogen	SYM	estrogen	estrogen	estrogen	Y	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
ancillary	JJ	ancillary	ancillary	ancillari	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
WHI	NNP	whi	whi	whi	N	O
reported	VBD	reported	reported	report	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
probable	JJ	probable	probable	probabl	N	O
dementia	NN	dementia	dementia	dementia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
\n	FW	\n	\n	\n	N	O
\n\n\n\n\n\n\n\n	FW	\n\n\n\n\n\n\n\n	\n\n\n\n\n\n\n\n	\n\n\n\n\n\n\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
Patient	NNP	patient	patient	patient	N	O
InformationDUAVEE	NNP	informationduavee	informationduavee	informationduave	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
DEW	NNP	dew	dew	dew	N	O
ah	VBZ	ah	ah	ah	N	O
-	:	-	-	-	N	O
vee	NN	vee	vee	vee	N	O
)(	NN	)(	)(	)(	N	O
conjugated	VBD	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
)	)	)	)	)	N	O
Tablets	VBZ	tablets	tablet	tablet	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Read	NNP	read	read	read	N	O
this	DT	this	this	thi	N	O
Patient	NNP	patient	patient	patient	N	O
Information	NN	information	information	inform	N	O
before	IN	before	before	befor	N	O
you	PRP	you	you	you	N	O
start	VBP	start	start	start	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
and	CC	and	and	and	N	O
each	DT	each	each	each	N	O
time	NN	time	time	time	N	O
you	PRP	you	you	you	N	O
get	VBP	get	get	get	N	O
a	DT	a	a	a	N	O
refill	NN	refill	refill	refil	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
new	JJ	new	new	new	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
information	NN	information	information	inform	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
the	DT	the	the	the	N	O
place	NN	place	place	place	N	O
of	IN	of	of	of	N	O
talking	VBG	talking	talking	talk	N	O
to	TO	to	to	to	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
about	IN	about	about	about	N	O
your	PRP$	your	your	your	N	O
medical	JJ	medical	medical	medic	N	O
condition	NN	condition	condition	condit	N	O
or	CC	or	or	or	N	O
your	PRP$	your	your	your	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

What	WP	what	what	what	N	O
is	VBZ	is	is	is	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
important	JJ	important	important	import	N	O
information	NN	information	information	inform	N	O
I	PRP	i	i	i	N	O
should	MD	should	should	should	N	O
know	VB	know	know	know	N	O
about	IN	about	about	about	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Do	VB	do	do	do	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
additional	JJ	additional	additional	addit	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
products	NNS	products	product	product	N	O
while	IN	while	while	while	N	O
you	PRP	you	you	you	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

Using	VBG	using	using	use	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
your	PRP$	your	your	your	N	O
chance	NN	chance	chance	chanc	N	O
of	IN	of	of	of	N	O
getting	VBG	getting	getting	get	N	O
cancer	NN	cancer	cancer	cancer	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
uterus	NN	uterus	uterus	uteru	N	O
(	(	(	(	(	N	O
womb	NN	womb	womb	womb	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Report	NNP	report	report	report	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
right	RB	right	right	right	N	O
away	RB	away	away	away	N	O
while	IN	while	while	while	N	O
you	PRP	you	you	you	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

Vaginal	NNP	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
after	IN	after	after	after	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
warning	VBG	warning	warning	warn	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
cancer	NN	cancer	cancer	cancer	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
uterus	NN	uterus	uterus	uteru	N	O
(	(	(	(	(	N	O
womb	NN	womb	womb	womb	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
check	VB	check	check	check	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
to	TO	to	to	to	N	O
find	VB	find	find	find	N	O
out	RP	out	out	out	N	O
the	DT	the	the	the	N	O
cause	NN	cause	cause	caus	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
to	TO	to	to	to	N	O
prevent	VB	prevent	prevent	prevent	N	O
heart	NN	heart	heart	heart	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
heart	NN	heart	heart	heart	N	O
attacks	NNS	attacks	attack	attack	N	O
,	,	,	,	,	N	O
strokes	NNS	strokes	stroke	stroke	N	O
or	CC	or	or	or	N	O
dementia	NN	dementia	dementia	dementia	Y	O
(	(	(	(	(	N	O
decline	NN	decline	decline	declin	N	O
in	IN	in	in	in	N	O
brain	NN	brain	brain	brain	N	O
function	NN	function	function	function	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Using	VBG	using	using	use	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
your	PRP$	your	your	your	N	O
chances	NNS	chances	chance	chanc	N	O
of	IN	of	of	of	N	O
getting	VBG	getting	getting	get	N	O
strokes	NNS	strokes	stroke	stroke	N	O
or	CC	or	or	or	N	O
blood	NN	blood	blood	blood	N	O
clots	NNS	clots	clot	clot	N	O
.	.	.	.	.	N	O

Using	VBG	using	using	use	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
your	PRP$	your	your	your	N	O
chance	NN	chance	chance	chanc	N	O
of	IN	of	of	of	N	O
getting	VBG	getting	getting	get	N	O
dementia	NN	dementia	dementia	dementia	Y	O
,	,	,	,	,	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
women	NNS	women	woman	women	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
and	CC	and	and	and	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
talk	VB	talk	talk	talk	N	O
regularly	RB	regularly	regularly	regularli	N	O
about	IN	about	about	about	N	O
whether	IN	whether	whether	whether	N	O
you	PRP	you	you	you	N	O
still	RB	still	still	still	N	O
need	VB	need	need	need	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

What	WP	what	what	what	N	O
is	VBZ	is	is	is	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
prescription	NN	prescription	prescription	prescript	N	O
medicine	NN	medicine	medicine	medicin	N	O
that	WDT	that	that	that	N	O
contains	VBZ	contains	contains	contain	N	O
a	DT	a	a	a	N	O
mixture	NN	mixture	mixture	mixtur	N	O
of	IN	of	of	of	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
and	CC	and	and	and	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
.	.	.	.	.	N	O

What	WP	what	what	what	N	O
is	VBZ	is	is	is	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
?	.	?	?	?	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
after	IN	after	after	after	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
for	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
uterus	JJ	uterus	uterus	uteru	N	O
to	TO	to	to	to	N	O
:	:	:	:	:	N	O
\n\n\n\n	VB	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
reduce	VB	reduce	reduce	reduc	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
hot	JJ	hot	hot	hot	N	O
flushesEstrogens	NNS	flushesestrogens	flushesestrogens	flushesestrogen	N	O
are	VBP	are	are	are	N	O
hormones	NNS	hormones	hormone	hormon	N	O
made	VBN	made	made	made	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
woman	NN	woman	woman	woman	N	O
's	POS	's	's	's	N	O
ovaries	NNS	ovaries	ovary	ovari	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
ovaries	NNS	ovaries	ovary	ovari	N	O
normally	RB	normally	normally	normal	N	O
stop	VB	stop	stop	stop	N	O
making	VBG	making	making	make	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
when	WRB	when	when	when	N	O
a	DT	a	a	a	N	O
woman	NN	woman	woman	woman	N	O
is	VBZ	is	is	is	N	O
between	IN	between	between	between	N	O
45	CD	45	45	45	N	O
and	CC	and	and	and	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
drop	NN	drop	drop	drop	N	O
in	IN	in	in	in	N	O
body	NN	body	body	bodi	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
levels	NNS	levels	level	level	N	O
causes	VBZ	causes	cause	caus	N	O
the	DT	the	the	the	N	O
"	JJ	"	"	"	N	O
change	NN	change	change	chang	N	O
of	IN	of	of	of	N	O
life	NN	life	life	life	N	O
"	NN	"	"	"	N	O
or	CC	or	or	or	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
(	(	(	(	(	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
monthly	JJ	monthly	monthly	monthli	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	O
periods	NNS	periods	period	period	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Sometimes	RB	sometimes	sometimes	sometim	N	O
both	DT	both	both	both	N	O
ovaries	NNS	ovaries	ovary	ovari	N	O
are	VBP	are	are	are	N	O
removed	VBN	removed	removed	remov	N	O
during	IN	during	during	dure	N	O
an	DT	an	an	an	N	O
operation	NN	operation	operation	oper	N	O
before	IN	before	before	befor	N	O
natural	JJ	natural	natural	natur	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
takes	VBZ	takes	take	take	N	O
place	NN	place	place	place	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
sudden	JJ	sudden	sudden	sudden	N	O
drop	NN	drop	drop	drop	N	O
in	IN	in	in	in	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
levels	NNS	levels	level	level	N	O
causes	VBZ	causes	cause	caus	N	O
"	JJ	"	"	"	N	O
surgical	JJ	surgical	surgical	surgic	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
.	.	.	.	.	N	O

"	NN	"	"	"	N	O
When	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
levels	NNS	levels	level	level	N	O
begin	VBP	begin	begin	begin	N	O
dropping	VBG	dropping	dropping	drop	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
women	NNS	women	woman	women	N	O
get	VBP	get	get	get	N	O
very	RB	very	very	veri	N	O
uncomfortable	JJ	uncomfortable	uncomfortable	uncomfort	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
feelings	NNS	feelings	feeling	feel	N	O
of	IN	of	of	of	N	O
warmth	NN	warmth	warmth	warmth	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
face	NN	face	face	face	N	O
,	,	,	,	,	N	O
neck	NN	neck	neck	neck	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
chest	JJS	chest	chest	chest	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
sudden	JJ	sudden	sudden	sudden	N	O
intense	JJ	intense	intense	intens	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
heat	NN	heat	heat	heat	N	O
and	CC	and	and	and	N	O
sweating	NN	sweating	sweating	sweat	Y	O
(	(	(	(	(	N	O
"	JJ	"	"	"	N	O
hot	JJ	hot	hot	hot	N	O
flashes	NNS	flashes	flash	flash	N	O
"	VBP	"	"	"	N	O
or	CC	or	or	or	N	O
"	VBP	"	"	"	N	O
hot	JJ	hot	hot	hot	N	O
flushes	NNS	flushes	flush	flush	N	O
"	VBP	"	"	"	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
women	NNS	women	woman	women	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
are	VBP	are	are	are	N	O
mild	JJ	mild	mild	mild	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
they	PRP	they	they	they	N	O
will	MD	will	will	will	N	O
not	RB	not	not	not	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
medicines	NNS	medicines	medicine	medicin	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
women	NNS	women	woman	women	N	O
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
more	RBR	more	more	more	N	O
severe	JJ	severe	severe	sever	N	O
.	.	.	.	.	N	O

help	NN	help	help	help	N	O
reduce	VB	reduce	reduce	reduc	N	O
your	PRP$	your	your	your	N	O
chances	NNS	chances	chance	chanc	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
(	(	(	(	(	N	O
thin	JJ	thin	thin	thin	N	O
,	,	,	,	,	N	O
weak	JJ	weak	weak	weak	N	O
bones	NNS	bones	bone	bone	N	O
)	)	)	)	)	N	O
If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
use	VBP	use	use	use	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
only	RB	only	only	onli	N	O
to	TO	to	to	to	N	O
prevent	VB	prevent	prevent	prevent	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
menopause	VB	menopause	menopause	menopaus	Y	O
,	,	,	,	,	N	O
talk	VB	talk	talk	talk	N	O
with	IN	with	with	with	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
about	IN	about	about	about	N	O
whether	IN	whether	whether	whether	N	O
a	DT	a	a	a	N	O
different	JJ	different	different	differ	N	O
treatment	NN	treatment	treatment	treatment	N	O
or	CC	or	or	or	N	O
medicine	NN	medicine	medicine	medicin	N	O
without	IN	without	without	without	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
might	MD	might	might	might	N	O
be	VB	be	be	be	N	O
better	JJR	better	better	better	N	O
for	IN	for	for	for	N	O
you	PRP	you	you	you	N	O
.	.	.	.	.	N	O
DUAVEE	VB	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
shortest	JJS	shortest	shortest	shortest	N	O
time	NN	time	time	time	N	O
possible	JJ	possible	possible	possibl	N	O
and	CC	and	and	and	N	O
only	RB	only	only	onli	N	O
for	IN	for	for	for	N	O
as	RB	as	a	as	N	O
long	JJ	long	long	long	N	O
as	IN	as	a	as	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
and	CC	and	and	and	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
talk	VB	talk	talk	talk	N	O
regularly	RB	regularly	regularly	regularli	N	O
about	IN	about	about	about	N	O
whether	IN	whether	whether	whether	N	O
you	PRP	you	you	you	N	O
still	RB	still	still	still	N	O
need	VB	need	need	need	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
if	IN	if	if	if	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
safe	JJ	safe	safe	safe	N	O
and	CC	and	and	and	N	O
effective	JJ	effective	effective	effect	N	O
in	IN	in	in	in	N	O
people	NNS	people	people	peopl	N	O
with	IN	with	with	with	N	O
kidney	NN	kidney	kidney	kidney	N	O
problems	NNS	problems	problem	problem	N	O
.	.	.	.	.	N	O

Who	WP	who	who	who	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Do	VB	do	do	do	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
:	:	:	:	:	N	O
\n\n\n\n	VB	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
currently	RB	currently	currently	current	N	O
have	VBP	have	have	have	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
blood	VBN	blood	blood	blood	N	O
clots	NNS	clots	clot	clot	N	O
\n	NNS	\n	\n	\n	N	O
are	VBP	are	are	are	N	O
allergic	JJ	allergic	allergic	allerg	N	O
to	TO	to	to	to	N	O
estrogens	VB	estrogens	estrogen	estrogen	N	O
or	CC	or	or	or	N	O
bazedoxifene	VB	bazedoxifene	bazedoxifene	bazedoxifen	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
its	PRP$	its	it	it	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
.	.	.	.	.	N	O

See	VB	see	see	see	N	O
the	DT	the	the	the	N	O
list	NN	list	list	list	N	O
of	IN	of	of	of	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
leaflet	NN	leaflet	leaflet	leaflet	N	O
.	.	.	.	.	N	O

have	VBP	have	have	have	N	O
unusual	JJ	unusual	unusual	unusu	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

Vaginal	NNP	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
after	IN	after	after	after	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
warning	VBG	warning	warning	warn	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
cancer	NN	cancer	cancer	cancer	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
uterus	NN	uterus	uterus	uteru	N	O
(	(	(	(	(	N	O
womb	NN	womb	womb	womb	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
check	VB	check	check	check	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
to	TO	to	to	to	N	O
find	VB	find	find	find	N	O
out	RP	out	out	out	N	O
the	DT	the	the	the	N	O
cause	NN	cause	cause	caus	N	O
.	.	.	.	.	N	O

currently	RB	currently	currently	current	N	O
have	VBP	have	have	have	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
certain	JJ	certain	certain	certain	N	O
cancers	NNS	cancers	cancer	cancer	N	O
.	.	.	.	.	N	O

Estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
chances	NNS	chances	chance	chanc	N	O
of	IN	of	of	of	N	O
getting	VBG	getting	getting	get	N	O
certain	JJ	certain	certain	certain	N	O
types	NNS	types	type	type	N	O
of	IN	of	of	of	N	O
cancers	NNS	cancers	cancer	cancer	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cancer	NN	cancer	cancer	cancer	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
breast	NN	breast	breast	breast	N	O
or	CC	or	or	or	N	O
uterus	NN	uterus	uterus	uteru	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
have	VBP	have	have	have	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
cancer	NN	cancer	cancer	cancer	Y	O
,	,	,	,	,	N	O
talk	NN	talk	talk	talk	N	O
with	IN	with	with	with	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
about	IN	about	about	about	N	O
whether	IN	whether	whether	whether	N	O
you	PRP	you	you	you	N	O
should	MD	should	should	should	N	O
use	VB	use	use	use	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

currently	RB	currently	currently	current	N	O
have	VBP	have	have	have	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
liver	VBN	liver	liver	liver	N	O
problems	NNS	problems	problem	problem	N	O
\n	WDT	\n	\n	\n	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
disorder	NN	disorder	disorder	disord	N	O
\n	FW	\n	\n	\n	N	O
think	VBP	think	think	think	N	O
you	PRP	you	you	you	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
.	.	.	.	.	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
for	IN	for	for	for	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
think	VBP	think	think	think	N	O
you	PRP	you	you	you	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
,	,	,	,	,	N	O
you	PRP	you	you	you	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
test	NN	test	test	test	N	O
and	CC	and	and	and	N	O
know	VB	know	know	know	N	O
the	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
.	.	.	.	.	N	O

Do	VB	do	do	do	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
test	NN	test	test	test	N	O
is	VBZ	is	is	is	N	O
positive	JJ	positive	positive	posit	N	O
and	CC	and	and	and	N	O
talk	VB	talk	talk	talk	N	O
to	TO	to	to	to	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
.	.	.	.	.	N	O

are	VBP	are	are	are	N	O
breastfeeding	VBG	breastfeeding	breastfeeding	breastfeed	N	O
or	CC	or	or	or	N	O
plan	NN	plan	plan	plan	N	O
to	TO	to	to	to	N	O
breastfeed	VB	breastfeed	breastfeed	breastfe	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
if	IN	if	if	if	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
passes	VBZ	passes	pass	pass	N	O
into	IN	into	into	into	N	O
your	PRP$	your	your	your	N	O
breast	NN	breast	breast	breast	N	O
milk	NN	milk	milk	milk	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
and	CC	and	and	and	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
decide	VB	decide	decide	decid	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
will	MD	will	will	will	N	O
take	VB	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
or	CC	or	or	or	N	O
breastfeed	VBN	breastfeed	breastfeed	breastfe	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
do	VB	do	do	do	N	O
both	DT	both	both	both	N	O
.	.	.	.	.	N	O

What	WP	what	what	what	N	O
should	MD	should	should	should	N	O
I	PRP	i	i	i	N	O
tell	VB	tell	tell	tell	N	O
my	PRP$	my	my	my	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
before	IN	before	before	befor	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Before	IN	before	before	befor	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
,	,	,	,	,	N	O
tell	VB	tell	tell	tell	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
:	:	:	:	:	N	O
\n\n\n\n	NNS	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
have	VBP	have	have	have	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

have	VBP	have	have	have	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
medical	JJ	medical	medical	medic	N	O
conditions	NNS	conditions	condition	condit	N	O
.	.	.	.	.	N	O

Your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
check	VB	check	check	check	N	O
you	PRP	you	you	you	N	O
more	RBR	more	more	more	N	O
carefully	RB	carefully	carefully	care	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
have	VBP	have	have	have	N	O
certain	JJ	certain	certain	certain	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
asthma	NN	asthma	asthma	asthma	Y	O
(	(	(	(	(	N	O
wheezing	VBG	wheezing	wheezing	wheez	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
epilepsy	FW	epilepsy	epilepsy	epilepsi	Y	O
(	(	(	(	(	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
,	,	,	,	,	N	O
migraine	NN	migraine	migraine	migrain	Y	O
,	,	,	,	,	N	O
endometriosis	NN	endometriosis	endometriosis	endometriosi	Y	O
,	,	,	,	,	N	O
lupus	NN	lupus	lupus	lupu	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
problems	NNS	problems	problem	problem	N	O
with	IN	with	with	with	N	O
your	PRP$	your	your	your	N	O
heart	NN	heart	heart	heart	N	O
,	,	,	,	,	N	O
liver	RB	liver	liver	liver	N	O
,	,	,	,	,	N	O
thyroid	NN	thyroid	thyroid	thyroid	N	O
,	,	,	,	,	N	O
kidneys	NNS	kidneys	kidney	kidney	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
high	JJ	high	high	high	N	O
calcium	NN	calcium	calcium	calcium	Y	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
your	PRP$	your	your	your	N	O
blood	NN	blood	blood	blood	N	O
.	.	.	.	.	N	O

are	VBP	are	are	are	N	O
going	VBG	going	going	go	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
or	CC	or	or	or	N	O
will	MD	will	will	will	N	O
be	VB	be	be	be	N	O
on	IN	on	on	on	N	O
bed	NN	bed	bed	bed	N	O
rest	NN	rest	rest	rest	N	O
.	.	.	.	.	N	O

Your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
will	MD	will	will	will	N	O
let	VB	let	let	let	N	O
you	PRP	you	you	you	N	O
know	VB	know	know	know	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
need	VBP	need	need	need	N	O
to	TO	to	to	to	N	O
stop	VB	stop	stop	stop	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

Tell	VB	tell	tell	tell	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
about	IN	about	about	about	N	O
all	PDT	all	all	all	N	O
the	DT	the	the	the	N	O
medicines	NNS	medicines	medicine	medicin	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
prescription	NN	prescription	prescription	prescript	N	O
and	CC	and	and	and	N	O
over	IN	over	over	over	N	O
-	:	-	-	-	N	O
the	DT	the	the	the	N	O
-	:	-	-	-	N	O
counter	NN	counter	counter	counter	N	O
medicines	NNS	medicines	medicine	medicin	N	O
,	,	,	,	,	N	O
vitamins	NNS	vitamins	vitamin	vitamin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
herbal	JJ	herbal	herbal	herbal	N	O
supplements	NNS	supplements	supplement	supplement	N	O
.	.	.	.	.	N	O

Especially	RB	especially	especially	especi	N	O
tell	VB	tell	tell	tell	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
other	JJ	other	other	other	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
medicines	NNS	medicines	medicine	medicin	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
progestins	NNS	progestins	progestin	progestin	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
medicines	NNS	medicines	medicine	medicin	N	O
like	IN	like	like	like	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

Ask	VB	ask	ask	ask	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
know	VB	know	know	know	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
medicines	NNS	medicines	medicine	medicin	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
medicines	NNS	medicines	medicine	medicin	N	O
may	MD	may	may	may	N	O
affect	VB	affect	affect	affect	N	O
how	WRB	how	how	how	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
works	VBZ	works	work	work	N	O
.	.	.	.	.	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
affect	VB	affect	affect	affect	N	O
how	WRB	how	how	how	N	O
your	PRP$	your	your	your	N	O
other	JJ	other	other	other	N	O
medicines	NNS	medicines	medicine	medicin	N	O
work	NN	work	work	work	N	O
.	.	.	.	.	N	O

Keep	VB	keep	keep	keep	N	O
a	DT	a	a	a	N	O
list	NN	list	list	list	N	O
of	IN	of	of	of	N	O
your	PRP$	your	your	your	N	O
medicines	NNS	medicines	medicine	medicin	N	O
and	CC	and	and	and	N	O
show	VB	show	show	show	N	O
it	PRP	it	it	it	N	O
to	TO	to	to	to	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
and	CC	and	and	and	N	O
pharmacist	NN	pharmacist	pharmacist	pharmacist	N	O
when	WRB	when	when	when	N	O
you	PRP	you	you	you	N	O
get	VBP	get	get	get	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
medicine	NN	medicine	medicine	medicin	N	O
.	.	.	.	.	N	O

How	WRB	how	how	how	N	O
should	MD	should	should	should	N	O
I	PRP	i	i	i	N	O
take	VB	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
comes	VBZ	comes	come	come	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
blister	NN	blister	blister	blister	Y	O
package	NN	package	package	packag	N	O
.	.	.	.	.	N	O

Record	NN	record	record	record	N	O
the	DT	the	the	the	N	O
date	NN	date	date	date	N	O
you	PRP	you	you	you	N	O
open	VBP	open	open	open	N	O
the	DT	the	the	the	N	O
foil	NN	foil	foil	foil	N	O
pouch	NN	pouch	pouch	pouch	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
space	NN	space	space	space	N	O
provided	VBD	provided	provided	provid	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
blister	NN	blister	blister	blister	Y	O
package	NN	package	package	packag	N	O
label	NN	label	label	label	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
blister	NN	blister	blister	blister	Y	O
package	NN	package	package	packag	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
open	JJ	open	open	open	N	O
for	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Take	VB	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
exactly	RB	exactly	exactly	exactli	N	O
as	IN	as	a	as	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
tells	VBZ	tells	tell	tell	N	O
you	PRP	you	you	you	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
it	PRP	it	it	it	N	O
.	.	.	.	.	N	O

Take	VB	take	take	take	N	O
1	CD	1	1	1	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
tablet	NN	tablet	tablet	tablet	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
time	NN	time	time	time	N	O
each	DT	each	each	each	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
swallowed	VBN	swallowed	swallowed	swallow	N	O
whole	JJ	whole	whole	whole	N	O
.	.	.	.	.	N	O

Take	VB	take	take	take	N	O
DUAVEE	NN	duavee	duavee	duave	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
food	NN	food	food	food	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
remove	VB	remove	remove	remov	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
blister	NN	blister	blister	blister	Y	O
until	IN	until	until	until	N	O
right	JJ	right	right	right	N	O
before	IN	before	before	befor	N	O
you	PRP	you	you	you	N	O
are	VBP	are	are	are	N	O
ready	JJ	ready	ready	readi	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
it	PRP	it	it	it	N	O
.	.	.	.	.	N	O

Remove	VB	remove	remove	remov	N	O
1	CD	1	1	1	N	O
tablet	NN	tablet	tablet	tablet	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
time	NN	time	time	time	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
blister	NN	blister	blister	blister	Y	O
package	NN	package	package	packag	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
place	VB	place	place	place	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
in	IN	in	in	in	N	O
pill	NN	pill	pill	pill	N	O
boxes	NNS	boxes	box	box	N	O
or	CC	or	or	or	N	O
pill	NN	pill	pill	pill	N	O
organizers	NNS	organizers	organizer	organ	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
miss	VBP	miss	miss	miss	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
,	,	,	,	,	N	O
take	VB	take	take	take	N	O
it	PRP	it	it	it	N	O
as	RB	as	a	as	N	O
soon	RB	soon	soon	soon	N	O
as	IN	as	a	as	N	O
you	PRP	you	you	you	N	O
remember	VBP	remember	remember	rememb	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
almost	RB	almost	almost	almost	N	O
time	NN	time	time	time	N	O
for	IN	for	for	for	N	O
your	PRP$	your	your	your	N	O
next	JJ	next	next	next	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
skip	VBD	skip	skip	skip	N	O
the	DT	the	the	the	N	O
missed	VBN	missed	missed	miss	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Take	VB	take	take	take	N	O
the	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
dose	NN	dose	dose	dose	N	O
at	IN	at	at	at	N	O
your	PRP$	your	your	your	N	O
regular	JJ	regular	regular	regular	N	O
time	NN	time	time	time	N	O
.	.	.	.	.	N	O

Do	VB	do	do	do	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
2	CD	2	2	2	N	O
doses	NNS	doses	dos	dose	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
time	NN	time	time	time	N	O
unless	IN	unless	unless	unless	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
tells	VBZ	tells	tell	tell	N	O
you	PRP	you	you	you	N	O
to	TO	to	to	to	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
sure	JJ	sure	sure	sure	N	O
about	IN	about	about	about	N	O
your	PRP$	your	your	your	N	O
dosing	NN	dosing	dosing	dose	N	O
,	,	,	,	,	N	O
call	VB	call	call	call	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
a	DT	a	a	a	N	O
calcium	NN	calcium	calcium	calcium	Y	O
or	CC	or	or	or	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
D	NNP	d	d	d	N	O
supplement	NN	supplement	supplement	supplement	N	O
,	,	,	,	,	N	O
you	PRP	you	you	you	N	O
may	MD	may	may	may	N	O
take	VB	take	take	take	N	O
it	PRP	it	it	it	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
time	NN	time	time	time	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
take	VBP	take	take	take	N	O
too	RB	too	too	too	N	O
much	JJ	much	much	much	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
,	,	,	,	,	N	O
call	VB	call	call	call	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
taking	VBG	taking	taking	take	N	O
too	RB	too	too	too	N	O
much	JJ	much	much	much	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
include	NN	include	include	includ	N	O
:	:	:	:	:	N	O
nauseavomitingbreast	JJ	nauseavomitingbreast	nauseavomitingbreast	nauseavomitingbreast	N	O
tendernessdizzinessabdominal	JJ	tendernessdizzinessabdominal	tendernessdizzinessabdominal	tendernessdizzinessabdomin	N	O
painfeeling	VBG	painfeeling	painfeeling	painfeel	N	O
tiredvaginal	JJ	tiredvaginal	tiredvaginal	tiredvagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
\n	VB	\n	\n	\n	N	O
What	WP	what	what	what	N	O
are	VBP	are	are	are	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
are	VBP	are	are	are	N	O
grouped	VBN	grouped	grouped	group	N	O
by	IN	by	by	by	N	O
how	WRB	how	how	how	N	O
serious	JJ	serious	serious	seriou	N	O
they	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
and	CC	and	and	and	N	O
how	WRB	how	how	how	N	O
often	RB	often	often	often	N	O
they	PRP	they	they	they	N	O
happen	VBP	happen	happen	happen	N	O
when	WRB	when	when	when	N	O
you	PRP	you	you	you	N	O
are	VBP	are	are	are	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
blood	NN	blood	blood	blood	N	O
clots	NNS	clots	clot	clot	N	O
\n	VBP	\n	\n	\n	N	O
stroke	NN	stroke	stroke	stroke	Y	O
\n	NNP	\n	\n	\n	N	O
heart	NN	heart	heart	heart	N	O
attack	NN	attack	attack	attack	N	O
\n	NNP	\n	\n	\n	N	O
cancer	NN	cancer	cancer	cancer	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
lining	NN	lining	lining	line	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
uterus	JJ	uterus	uterus	uteru	N	O
\n	NNP	\n	\n	\n	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
\n	NNP	\n	\n	\n	N	O
cancer	NN	cancer	cancer	cancer	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
ovary	JJ	ovary	ovary	ovari	N	O
\n	NNP	\n	\n	\n	N	O
dementia	NN	dementia	dementia	dementia	Y	O
\n	NNP	\n	\n	\n	N	O
gallbladder	NN	gallbladder	gallbladder	gallbladd	N	O
problems	NNS	problems	problem	problem	N	O
\n	VBP	\n	\n	\n	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
\n	NNP	\n	\n	\n	N	O
high	JJ	high	high	high	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
\n	NNP	\n	\n	\n	N	O
increased	VBD	increased	increased	increas	N	O
fats	NNS	fats	fat	fat	N	O
in	IN	in	in	in	N	O
your	PRP$	your	your	your	N	O
blood	NN	blood	blood	blood	N	O
\n	NN	\n	\n	\n	N	O
liver	NN	liver	liver	liver	N	O
problems	NNS	problems	problem	problem	N	O
\n	VBP	\n	\n	\n	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
problems	NNS	problems	problem	problem	N	O
\n	VBP	\n	\n	\n	N	O
fluid	JJ	fluid	fluid	fluid	N	O
retention	NN	retention	retention	retent	N	O
\n	NNP	\n	\n	\n	N	O
low	JJ	low	low	low	N	O
calcium	NN	calcium	calcium	calcium	Y	O
\n	NNP	\n	\n	\n	N	O
swelling	NN	swelling	swelling	swell	Y	O
of	IN	of	of	of	N	O
your	PRP$	your	your	your	N	O
mouth	NN	mouth	mouth	mouth	N	O
or	CC	or	or	or	N	O
tongue	NN	tongue	tongue	tongu	N	O
\n	IN	\n	\n	\n	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
medical	JJ	medical	medical	medic	N	O
problems	NNS	problems	problem	problem	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
,	,	,	,	,	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
,	,	,	,	,	N	O
migraines	NNS	migraines	migraine	migrain	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
genetic	JJ	genetic	genetic	genet	N	O
problem	NN	problem	problem	problem	N	O
called	VBN	called	called	call	N	O
porphyria	NN	porphyria	porphyria	porphyria	Y	O
,	,	,	,	,	N	O
lupus	NN	lupus	lupus	lupu	N	O
and	CC	and	and	and	N	O
liver	NN	liver	liver	liver	N	O
problems	NNS	problems	problem	problem	N	O
\n	VBP	\n	\n	\n	N	O
Call	VB	call	call	call	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
right	RB	right	right	right	N	O
away	RB	away	away	away	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
get	VBP	get	get	get	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
warning	NN	warning	warning	warn	N	O
signs	NNS	signs	sign	sign	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
unusual	JJ	unusual	unusual	unusu	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
concern	NN	concern	concern	concern	N	O
you	PRP	you	you	you	N	O
:	:	:	:	:	N	O
\n	VB	\n	\n	\n	N	O
\n\n	CD	\n\n	\n\n	\n\n	N	O
new	JJ	new	new	new	N	O
breast	NN	breast	breast	breast	N	O
lumps	NNS	lumps	lump	lump	N	O
\n	VBP	\n	\n	\n	N	O
unusual	JJ	unusual	unusual	unusu	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
\n	NN	\n	\n	\n	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
vision	NN	vision	vision	vision	N	O
or	CC	or	or	or	N	O
speech	NN	speech	speech	speech	N	O
\n	NNP	\n	\n	\n	N	O
sudden	JJ	sudden	sudden	sudden	N	O
new	JJ	new	new	new	N	O
severe	JJ	severe	severe	sever	N	O
headaches	NNS	headaches	headache	headach	N	O
\n	VBP	\n	\n	\n	N	O
severe	JJ	severe	severe	sever	N	O
pains	NNS	pains	pain	pain	N	O
in	IN	in	in	in	N	O
your	PRP$	your	your	your	N	O
chest	NN	chest	chest	chest	N	O
or	CC	or	or	or	N	O
legs	NN	legs	leg	leg	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
shortness	NN	shortness	shortness	short	N	O
of	IN	of	of	of	N	O
breath	NN	breath	breath	breath	N	O
,	,	,	,	,	N	O
weakness	NN	weakness	weakness	weak	Y	O
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
\n	NNP	\n	\n	\n	N	O
Less	NNP	less	le	less	N	O
serious	JJ	serious	serious	seriou	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
common	JJ	common	common	common	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
\n	JJ	\n	\n	\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
muscle	NN	muscle	muscle	muscl	N	O
spasms	NNS	spasms	spasm	spasm	Y	O
\n	VBP	\n	\n	\n	N	O
nausea	JJ	nausea	nausea	nausea	Y	O
\n	NNP	\n	\n	\n	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
\n	NNP	\n	\n	\n	N	O
upset	JJ	upset	upset	upset	N	O
stomach	NN	stomach	stomach	stomach	N	O
\n	NNP	\n	\n	\n	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
\n	NNP	\n	\n	\n	N	O
throat	NN	throat	throat	throat	N	O
pain	NN	pain	pain	pain	Y	O
\n	NNP	\n	\n	\n	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	O
\n	NNP	\n	\n	\n	N	O
neck	NN	neck	neck	neck	N	O
pain	NN	pain	pain	pain	Y	O
\n	IN	\n	\n	\n	N	O
These	DT	these	these	these	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
all	PDT	all	all	all	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
information	NN	information	information	inform	N	O
,	,	,	,	,	N	O
ask	VB	ask	ask	ask	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
or	CC	or	or	or	N	O
pharmacist	NN	pharmacist	pharmacist	pharmacist	N	O
.	.	.	.	.	N	O

Tell	VB	tell	tell	tell	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
have	VBP	have	have	have	N	O
any	DT	any	any	ani	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
that	IN	that	that	that	N	O
bother	VBP	bother	bother	bother	N	O
you	PRP	you	you	you	N	O
or	CC	or	or	or	N	O
do	VB	do	do	do	N	O
not	RB	not	not	not	N	O
go	VB	go	go	go	N	O
away	RB	away	away	away	N	O
.	.	.	.	.	N	O

Call	VB	call	call	call	N	O
your	PRP$	your	your	your	N	O
doctor	NN	doctor	doctor	doctor	N	O
for	IN	for	for	for	N	O
medical	JJ	medical	medical	medic	N	O
advice	NN	advice	advice	advic	N	O
about	IN	about	about	about	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
may	MD	may	may	may	N	O
report	VB	report	report	report	N	O
side	NN	side	side	side	N	O
effects	NNS	effects	effect	effect	N	O
to	TO	to	to	to	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
.	.	.	.	.	N	O

What	WP	what	what	what	N	O
can	MD	can	can	can	N	O
I	PRP	i	i	i	N	O
do	VB	do	do	do	N	O
to	TO	to	to	to	N	O
lower	VB	lower	lower	lower	N	O
my	PRP$	my	my	my	N	O
chances	NNS	chances	chance	chanc	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
side	NN	side	side	side	N	O
effect	NN	effect	effect	effect	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Talk	NN	talk	talk	talk	N	O
with	IN	with	with	with	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
regularly	RB	regularly	regularly	regularli	N	O
about	IN	about	about	about	N	O
whether	IN	whether	whether	whether	N	O
you	PRP	you	you	you	N	O
should	MD	should	should	should	N	O
continue	VB	continue	continue	continu	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

See	VB	see	see	see	N	O
you	PRP	you	you	you	N	O
healthcare	VB	healthcare	healthcare	healthcar	N	O
provider	VB	provider	provider	provid	N	O
right	RB	right	right	right	N	O
away	RB	away	away	away	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
get	VBP	get	get	get	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

Have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
pelvic	JJ	pelvic	pelvic	pelvic	N	O
exam	NN	exam	exam	exam	N	O
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	O
exam	NN	exam	exam	exam	N	O
and	CC	and	and	and	N	O
mammogram	NN	mammogram	mammogram	mammogram	Y	O
(	(	(	(	(	N	O
breast	NN	breast	breast	breast	N	O
X	NNP	x	x	x	N	O
-	:	-	-	-	N	O
ray	NN	ray	ray	ray	N	O
)	)	)	)	)	N	O
every	DT	every	every	everi	N	O
year	NN	year	year	year	N	O
unless	IN	unless	unless	unless	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
tells	NNS	tells	tell	tell	N	O
you	PRP	you	you	you	N	O
something	NN	something	something	someth	N	O
else	RB	else	else	els	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
members	NNS	members	member	member	N	O
of	IN	of	of	of	N	O
your	PRP$	your	your	your	N	O
family	NN	family	family	famili	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
breast	VBN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
have	VBP	have	have	have	N	O
ever	RB	ever	ever	ever	N	O
had	VBN	had	had	had	N	O
breast	VBN	breast	breast	breast	N	O
lumps	NNS	lumps	lump	lump	N	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
mammogram	NN	mammogram	mammogram	mammogram	Y	O
,	,	,	,	,	N	O
you	PRP	you	you	you	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
breast	VBN	breast	breast	breast	N	O
exams	NNS	exams	exam	exam	N	O
more	RBR	more	more	more	N	O
often	RB	often	often	often	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
have	VBP	have	have	have	N	O
high	JJ	high	high	high	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
high	JJ	high	high	high	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
fat	JJ	fat	fat	fat	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
blood	NN	blood	blood	blood	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
overweight	JJ	overweight	overweight	overweight	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
use	VBP	use	use	use	N	O
tobacco	NN	tobacco	tobacco	tobacco	N	O
,	,	,	,	,	N	O
you	PRP	you	you	you	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
higher	JJR	higher	higher	higher	N	O
chances	NNS	chances	chance	chanc	N	O
of	IN	of	of	of	N	O
getting	VBG	getting	getting	get	N	O
heart	NN	heart	heart	heart	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Ask	VB	ask	ask	ask	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
for	IN	for	for	for	N	O
ways	NNS	ways	way	way	N	O
to	TO	to	to	to	N	O
lower	VB	lower	lower	lower	N	O
your	PRP$	your	your	your	N	O
chances	NNS	chances	chance	chanc	N	O
of	IN	of	of	of	N	O
getting	VBG	getting	getting	get	N	O
heart	NN	heart	heart	heart	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

How	WRB	how	how	how	N	O
do	VBP	do	do	do	N	O
I	PRP	i	i	i	N	O
store	VB	store	store	store	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Store	NN	store	store	store	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
at	IN	at	at	at	N	O
room	NN	room	room	room	N	O
temperature	NN	temperature	temperature	temperatur	N	O
between	IN	between	between	between	N	O
68	CD	68	68	68	N	O
degrees	NNS	degrees	degree	degre	N	O
F	NNP	f	f	f	N	O
to	TO	to	to	to	N	O
77	CD	77	77	77	N	O
degrees	NNS	degrees	degree	degre	N	O
F	NNP	f	f	f	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
degrees	NNS	degrees	degree	degre	N	O
C	NNP	c	c	c	N	O
to	TO	to	to	to	N	O
25	CD	25	25	25	N	O
degrees	NNS	degrees	degree	degre	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Keep	NNP	keep	keep	keep	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
blister	NN	blister	blister	blister	Y	O
until	IN	until	until	until	N	O
you	PRP	you	you	you	N	O
are	VBP	are	are	are	N	O
ready	JJ	ready	ready	readi	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
it	PRP	it	it	it	N	O
to	TO	to	to	to	N	O
protect	VB	protect	protect	protect	N	O
the	DT	the	the	the	N	O
tablet	NN	tablet	tablet	tablet	N	O
from	IN	from	from	from	N	O
moisture	NN	moisture	moisture	moistur	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
place	VB	place	place	place	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
in	IN	in	in	in	N	O
pill	NN	pill	pill	pill	N	O
boxes	NNS	boxes	box	box	N	O
or	CC	or	or	or	N	O
pill	NN	pill	pill	pill	N	O
organizers	NNS	organizers	organizer	organ	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
opening	VBG	opening	opening	open	N	O
the	DT	the	the	the	N	O
foil	NN	foil	foil	foil	N	O
pouch	PDT	pouch	pouch	pouch	N	O
the	DT	the	the	the	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
blisters	NNS	blisters	blister	blister	Y	O
come	VBP	come	come	come	N	O
in	IN	in	in	in	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
within	IN	within	within	within	N	O
60	CD	60	60	60	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Keep	NNP	keep	keep	keep	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
other	JJ	other	other	other	N	O
medicines	NNS	medicines	medicine	medicin	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reach	NN	reach	reach	reach	N	O
of	IN	of	of	of	N	O
children	NNS	children	child	children	N	O
.	.	.	.	.	N	O

General	JJ	general	general	gener	N	O
information	NN	information	information	inform	N	O
about	IN	about	about	about	N	O
the	DT	the	the	the	N	O
safe	JJ	safe	safe	safe	N	O
and	CC	and	and	and	N	O
effective	JJ	effective	effective	effect	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Medicines	NNP	medicines	medicine	medicin	N	O
are	VBP	are	are	are	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
for	IN	for	for	for	N	O
purposes	NNS	purposes	purpose	purpos	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
those	DT	those	those	those	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
Patient	JJ	patient	patient	patient	N	O
Information	NNP	information	information	inform	N	O
leaflet	NN	leaflet	leaflet	leaflet	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
condition	NN	condition	condition	condit	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
it	PRP	it	it	it	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
give	VB	give	give	give	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
people	NNS	people	people	peopl	N	O
,	,	,	,	,	N	O
even	RB	even	even	even	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
have	VBP	have	have	have	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
you	PRP	you	you	you	N	O
have	VBP	have	have	have	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
may	MD	may	may	may	N	O
harm	VB	harm	harm	harm	N	O
them	PRP	them	them	them	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
Patient	NNP	patient	patient	patient	N	O
Information	NNP	information	information	inform	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
important	JJ	important	important	import	N	O
information	NN	information	information	inform	N	O
about	IN	about	about	about	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
you	PRP	you	you	you	N	O
would	MD	would	would	would	N	O
like	VB	like	like	like	N	O
more	JJR	more	more	more	N	O
information	NN	information	information	inform	N	O
,	,	,	,	,	N	O
talk	NN	talk	talk	talk	N	O
with	IN	with	with	with	N	O
your	PRP$	your	your	your	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
.	.	.	.	.	N	O

You	PRP	you	you	you	N	O
can	MD	can	can	can	N	O
ask	VB	ask	ask	ask	N	O
your	PRP$	your	your	your	N	O
pharmacist	NN	pharmacist	pharmacist	pharmacist	N	O
or	CC	or	or	or	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
for	IN	for	for	for	N	O
information	NN	information	information	inform	N	O
about	IN	about	about	about	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
written	VBN	written	written	written	N	O
for	IN	for	for	for	N	O
health	NN	health	health	health	N	O
professionals	NNS	professionals	professional	profession	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
information	NN	information	information	inform	N	O
,	,	,	,	,	N	O
go	VB	go	go	go	N	O
to	TO	to	to	to	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O
com	NN	com	com	com	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
call	VB	call	call	call	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
438	CD	438	438	438	N	O
-	:	-	-	-	N	O
1985	CD	1985	1985	1985	N	O
.	.	.	.	.	N	O

What	WP	what	what	what	N	O
are	VBP	are	are	are	N	O
the	DT	the	the	the	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
?	.	?	?	?	N	O

Active	JJ	active	active	activ	N	O
Ingredients	NNS	ingredients	ingredient	ingredi	N	O
:	:	:	:	:	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
and	CC	and	and	and	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
.	.	.	.	.	N	O

Conjugated	VBN	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
are	VBP	are	are	are	N	O
a	DT	a	a	a	N	O
mixture	NN	mixture	mixture	mixtur	N	O
of	IN	of	of	of	N	O
sodium	NN	sodium	sodium	sodium	Y	O
estrone	NN	estrone	estrone	estron	Y	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
and	CC	and	and	and	N	O
sodium	NN	sodium	sodium	sodium	Y	O
equilin	NN	equilin	equilin	equilin	N	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
components	NNS	components	component	compon	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
sodium	NN	sodium	sodium	sodium	Y	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
conjugates	NNS	conjugates	conjugate	conjug	N	O
,	,	,	,	,	N	O
17	CD	17	17	17	N	O
alpha	SYM	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
dihydroequilin	NN	dihydroequilin	dihydroequilin	dihydroequilin	N	O
,	,	,	,	,	N	O
17	CD	17	17	17	N	O
alpha	SYM	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
estradiol	NN	estradiol	estradiol	estradiol	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
17	CD	17	17	17	N	O
beta	NN	beta	beta	beta	N	O
-	:	-	-	-	N	O
dihydroequilin	NN	dihydroequilin	dihydroequilin	dihydroequilin	N	O
.	.	.	.	.	N	O

Inactive	JJ	inactive	inactive	inact	N	O
Ingredients	NNS	ingredients	ingredient	ingredi	N	O
:	:	:	:	:	N	O
calcium	NN	calcium	calcium	calcium	Y	O
phosphate	NN	phosphate	phosphate	phosphat	Y	O
tribasic	NN	tribasic	tribasic	tribas	N	O
,	,	,	,	,	N	O
hydroxypropyl	NN	hydroxypropyl	hydroxypropyl	hydroxypropyl	N	O
cellulose	NN	cellulose	cellulose	cellulos	N	O
,	,	,	,	,	N	O
microcrystalline	NN	microcrystalline	microcrystalline	microcrystallin	N	O
cellulose	NN	cellulose	cellulose	cellulos	N	O
,	,	,	,	,	N	O
powdered	VBD	powdered	powdered	powder	N	O
cellulose	NN	cellulose	cellulose	cellulos	N	O
,	,	,	,	,	N	O
hypromellose	NN	hypromellose	hypromellose	hypromellos	N	O
,	,	,	,	,	N	O
lactose	JJ	lactose	lactose	lactos	N	O
monohydrate	NN	monohydrate	monohydrate	monohydr	N	O
,	,	,	,	,	N	O
magnesium	NN	magnesium	magnesium	magnesium	Y	O
stearate	NN	stearate	stearate	stearat	N	O
,	,	,	,	,	N	O
polyethylene	NN	polyethylene	polyethylene	polyethylen	N	O
glycol	NN	glycol	glycol	glycol	N	O
,	,	,	,	,	N	O
sucrose	RB	sucrose	sucrose	sucros	N	O
,	,	,	,	,	N	O
ascorbic	JJ	ascorbic	ascorbic	ascorb	N	O
acid	NN	acid	acid	acid	N	O
,	,	,	,	,	N	O
sucrose	JJ	sucrose	sucrose	sucros	N	O
palmitic	JJ	palmitic	palmitic	palmit	N	O
acid	NN	acid	acid	acid	N	O
ester	NN	ester	ester	ester	N	O
,	,	,	,	,	N	O
hydroxyethylcellulose	NN	hydroxyethylcellulose	hydroxyethylcellulose	hydroxyethylcellulos	N	O
,	,	,	,	,	N	O
titanium	NN	titanium	titanium	titanium	N	O
dioxide	NN	dioxide	dioxide	dioxid	N	O
,	,	,	,	,	N	O
red	JJ	red	red	red	N	O
iron	NN	iron	iron	iron	Y	O
oxide	NN	oxide	oxide	oxid	N	O
,	,	,	,	,	N	O
yellow	JJ	yellow	yellow	yellow	N	O
iron	NN	iron	iron	iron	Y	O
oxide	NN	oxide	oxide	oxid	N	O
,	,	,	,	,	N	O
black	JJ	black	black	black	N	O
iron	NN	iron	iron	iron	Y	O
oxide	NN	oxide	oxide	oxid	N	O
,	,	,	,	,	N	O
povidone	NN	povidone	povidone	povidon	N	O
,	,	,	,	,	N	O
polydextrose	NN	polydextrose	polydextrose	polydextros	N	O
,	,	,	,	,	N	O
maltitol	NN	maltitol	maltitol	maltitol	N	O
,	,	,	,	,	N	O
poloxamer	NN	poloxamer	poloxamer	poloxam	N	O
188	CD	188	188	188	N	O
,	,	,	,	,	N	O
propylene	NN	propylene	propylene	propylen	N	O
glycol	NN	glycol	glycol	glycol	N	O
,	,	,	,	,	N	O
isopropyl	JJ	isopropyl	isopropyl	isopropyl	N	O
alcohol	NN	alcohol	alcohol	alcohol	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
Patient	NNP	patient	patient	patient	N	O
Information	NNP	information	information	inform	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
approved	VBN	approved	approved	approv	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
U.S.	NNP	u.s.	u.s.	u.s.	N	O

Food	NNP	food	food	food	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Administration	NNP	administration	administration	administr	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
product	NN	product	product	product	N	O
's	POS	's	's	's	N	O
label	NN	label	label	label	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
been	VBN	been	been	been	N	O
updated	VBN	updated	updated	updat	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
current	JJ	current	current	current	N	O
full	JJ	full	full	full	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
,	,	,	,	,	N	O
please	VB	please	please	pleas	N	O
visit	NN	visit	visit	visit	N	O
www	NN	www	www	www	N	O
.	.	.	.	.	N	O
pfizer	NN	pfizer	pfizer	pfizer	N	O
.	.	.	.	.	N	O
com	NN	com	com	com	N	O
.	.	.	.	.	N	O

LAB	NNP	lab	lab	lab	N	O
-	:	-	-	-	N	O
0583	CD	0583	0583	0583	N	O
-	:	-	-	-	N	O
1.0	CD	1.0	1.0	1.0	N	O
\n\n\n\n	IN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
October	NNP	october	october	octob	N	O
2013	CD	2013	2013	2013	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
progestins	NNS	progestins	progestin	progestin	N	O
,	,	,	,	,	N	O
additional	JJ	additional	additional	addit	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
or	CC	or	or	or	N	O
additional	JJ	additional	additional	addit	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
agonist	NN	agonist	agonist	agonist	N	O
antagonists	NNS	antagonists	antagonist	antagonist	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
,	,	,	,	,	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
vascular	JJ	vascular	vascular	vascular	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Malignant	JJ	malignant	malignant	malign	N	B-AdverseReaction
neoplasms	NNS	neoplasms	neoplasm	neoplasm	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ovarian	JJ	ovarian	ovarian	ovarian	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Estrogens	NNS	estrogens	estrogen	estrogen	N	O
increase	VBP	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
gallbladder	NN	gallbladder	gallbladder	gallbladd	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
if	IN	if	if	if	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	O
or	CC	or	or	or	N	O
cholestatic	JJ	cholestatic	cholestatic	cholestat	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
occurs	NNS	occurs	occurs	occur	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
,	,	,	,	,	N	O
5.8	CD	5.8	5.8	5.8	N	O
,	,	,	,	,	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
on	IN	on	on	on	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
,	,	,	,	,	N	O
5.17	CD	5.17	5.17	5.17	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Drugs	NNS	drugs	drug	drug	N	O

Containing	VBG	containing	containing	contain	N	O
Progestins	NNP	progestins	progestin	progestin	N	O
,	,	,	,	,	N	O
Estrogens	NNP	estrogens	estrogen	estrogen	N	O
or	CC	or	or	or	N	O
Estrogen	NNP	estrogen	estrogen	estrogen	Y	O
Agonist	NNP	agonist	agonist	agonist	N	O
Antagonists	NNS	antagonists	antagonist	antagonist	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
contains	NNS	contains	contains	contain	N	O
conjugated	VBD	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
and	CC	and	and	and	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
agonist	NN	agonist	agonist	agonist	N	O
antagonist	NN	antagonist	antagonist	antagonist	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
progestins	NNS	progestins	progestin	progestin	N	O
,	,	,	,	,	N	O
additional	JJ	additional	additional	addit	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
or	CC	or	or	or	N	O
additional	JJ	additional	additional	addit	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
agonist	NN	agonist	agonist	agonist	N	O
antagonists	NNS	antagonists	antagonist	antagonist	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Estrogen	NNP	estrogen	estrogen	estrogen	Y	O
agonist	NN	agonist	agonist	agonist	N	O
antagonists	NNS	antagonists	antagonist	antagonist	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
estrogens	VBZ	estrogens	estrogen	estrogen	N	O
individually	RB	individually	individually	individu	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
VTE	NNP	vte	vte	vte	N	B-AdverseReaction
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
and	CC	and	and	and	N	O
DVT	NNP	dvt	dvt	dvt	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Should	MD	should	should	should	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
occur	NNS	occur	occur	occur	N	O
or	CC	or	or	or	N	O
be	VB	be	be	be	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
arterial	JJ	arterial	arterial	arteri	N	O
vascular	JJ	vascular	vascular	vascular	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
,	,	,	,	,	N	O
tobacco	NN	tobacco	tobacco	tobacco	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
obesity	NN	obesity	obesity	obes	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
VTE	NNP	vte	vte	vte	N	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
personal	JJ	personal	personal	person	N	O
history	NN	history	history	histori	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
VTE	NNP	vte	vte	vte	N	O
,	,	,	,	,	N	O
obesity	NN	obesity	obesity	obes	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
systemic	JJ	systemic	systemic	system	N	O
lupus	NN	lupus	lupus	lupu	N	O
erythematosus	NN	erythematosus	erythematosus	erythematosu	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
managed	VBN	managed	managed	manag	N	O
appropriately	RB	appropriately	appropriately	appropri	N	O
.	.	.	.	.	N	O

Stroke	NN	stroke	stroke	stroke	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
substudy	NN	substudy	substudy	substudi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
statistically	RB	statistically	statistically	statist	N	O
significant	JJ	significant	significant	signific	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
50	CD	50	50	50	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
receiving	VBG	receiving	receiving	receiv	N	O
daily	RB	daily	daily	daili	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	B-DrugClass
estrogens	NNS	estrogens	estrogen	estrogen	N	I-DrugClass
(	(	(	(	(	N	O
CE	NNP	ce	ce	ce	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
women	NNS	women	woman	women	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
age	NN	age	age	age	N	O
group	NN	group	group	group	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
45	CD	45	45	45	N	O
versus	NN	versus	versus	versu	N	O
33	CD	33	33	33	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
women	NNS	women	woman	women	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
risk	NN	risk	risk	risk	N	O
was	VBD	was	wa	wa	N	O
demonstrated	VBN	demonstrated	demonstrated	demonstr	N	O
in	IN	in	in	in	N	O
year	NN	year	year	year	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
persisted	VBD	persisted	persisted	persist	N	O
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.5	CD	14.5	14.5	14.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Subgroup	NNP	subgroup	subgroup	subgroup	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
women	NNS	women	woman	women	N	O
50	CD	50	50	50	N	O
to	TO	to	to	to	N	O
59	CD	59	59	59	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
suggest	VBP	suggest	suggest	suggest	N	O
no	DT	no	no	no	N	B-Negation
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
for	IN	for	for	for	N	O
those	DT	those	those	those	N	O
women	NNS	women	woman	women	N	O
receiving	VBG	receiving	receiving	receiv	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	B-DrugClass
estrogens	NNS	estrogens	estrogen	estrogen	N	I-DrugClass
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
versus	VBP	versus	versus	versu	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
versus	NN	versus	versus	versu	N	O
21	CD	21	21	21	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
women	NNS	women	woman	women	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Should	MD	should	should	should	N	O
a	DT	a	a	a	N	O
stroke	NN	stroke	stroke	stroke	Y	O
occur	NN	occur	occur	occur	N	O
or	CC	or	or	or	N	O
be	VB	be	be	be	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Coronary	JJ	coronary	coronary	coronari	N	O
Heart	NNP	heart	heart	heart	N	O
Disease	NNP	disease	disease	diseas	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
substudy	NN	substudy	substudy	substudi	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
overall	JJ	overall	overall	overal	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
coronary	JJ	coronary	coronary	coronari	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
CHD	NNP	chd	chd	chd	N	B-AdverseReaction
)	)	)	)	)	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
nonfatal	JJ	nonfatal	nonfatal	nonfat	N	B-Severity
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
silent	JJ	silent	silent	silent	N	B-AdverseReaction
myocardial	JJ	myocardial	myocardial	myocardi	N	I-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
CHD	NNP	chd	chd	chd	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
receiving	VBG	receiving	receiving	receiv	N	O
estrogen	JJ	estrogen	estrogen	estrogen	Y	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.5	CD	14.5	14.5	14.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Subgroup	NNP	subgroup	subgroup	subgroup	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
women	NNS	women	woman	women	N	O
50	CD	50	50	50	N	O
to	TO	to	to	to	N	O
59	CD	59	59	59	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
suggest	VBP	suggest	suggest	suggest	N	O
a	DT	a	a	a	N	O
statistically	RB	statistically	statistically	statist	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
significant	JJ	significant	significant	signific	N	O
reduction	NN	reduction	reduction	reduct	N	B-Negation
in	IN	in	in	in	N	O
CHD	NNP	chd	chd	chd	N	B-AdverseReaction
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
CE	NNP	ce	ce	ce	N	O
[	VBZ	[	[	[	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	JJ	mg	mg	mg	N	O
]-	JJ	]-	]-	]-	N	O
alone	RB	alone	alone	alon	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10	CD	10	10	10	N	O
years	NNS	years	year	year	N	O
since	IN	since	since	sinc	N	O
menopause	NN	menopause	menopause	menopaus	Y	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
versus	NN	versus	versus	versu	N	O
16	CD	16	16	16	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
women	NNS	women	woman	women	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Venous	JJ	venous	venous	venou	N	O
Thromboembolism	NNP	thromboembolism	thromboembolism	thromboembol	Y	O
(	(	(	(	(	N	O
VTE	NNP	vte	vte	vte	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
substudy	NN	substudy	substudy	substudi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
VTE	NNP	vte	vte	vte	N	B-AdverseReaction
[	NNP	[	[	[	N	O
DVT	NNP	dvt	dvt	dvt	Y	B-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
PE	NNP	pe	pe	pe	N	B-AdverseReaction
)]	NNP	)]	)]	)]	N	O
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
for	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
receiving	VBG	receiving	receiving	receiv	N	O
daily	RB	daily	daily	daili	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	B-DrugClass
estrogens	NNS	estrogens	estrogen	estrogen	N	I-DrugClass
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
30	CD	30	30	30	N	O
versus	NN	versus	versus	versu	N	O
22	CD	22	22	22	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
women	NNS	women	woman	women	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
only	RB	only	only	onli	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
DVT	NNP	dvt	dvt	dvt	Y	B-AdverseReaction
reached	VBD	reached	reached	reach	N	O
statistical	JJ	statistical	statistical	statist	N	O
significance	NN	significance	significance	signific	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
versus	NN	versus	versus	versu	N	O
15	CD	15	15	15	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
women	NNS	women	woman	women	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
VTE	NNP	vte	vte	vte	N	B-AdverseReaction
risk	NN	risk	risk	risk	N	B-Factor
was	VBD	was	wa	wa	N	O
demonstrated	VBN	demonstrated	demonstrated	demonstr	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.5	CD	14.5	14.5	14.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
feasible	JJ	feasible	feasible	feasibl	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
4	CD	4	4	4	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
before	IN	before	before	befor	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
type	NN	type	type	type	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
during	IN	during	during	dure	N	O
periods	NNS	periods	period	period	N	O
of	IN	of	of	of	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
immobilization	NN	immobilization	immobilization	immobil	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
immobilization	NN	immobilization	immobilization	immobil	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
venous	JJ	venous	venous	venou	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
events	NNS	events	event	event	N	O
independent	JJ	independent	independent	independ	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
immobilization	NN	immobilization	immobilization	immobil	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
surgical	JJ	surgical	surgical	surgic	N	O
recovery	NN	recovery	recovery	recoveri	N	O
,	,	,	,	,	N	O
prolonged	VBD	prolonged	prolonged	prolong	N	O
bed	NN	bed	bed	bed	N	O
rest	NN	rest	rest	rest	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
resumed	VBN	resumed	resumed	resum	N	O
only	RB	only	only	onli	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
fully	RB	fully	fully	fulli	N	O
ambulatory	JJ	ambulatory	ambulatory	ambulatori	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
move	VB	move	move	move	N	O
about	RB	about	about	about	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
travel	NN	travel	travel	travel	N	O
involving	VBG	involving	involving	involv	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
immobilization	NN	immobilization	immobilization	immobil	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Malignant	JJ	malignant	malignant	malign	N	O
Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	O

Endometrial	JJ	endometrial	endometrial	endometri	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O

An	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
unopposed	JJ	unopposed	unopposed	unoppos	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	B-DrugClass
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
uterus	NN	uterus	uterus	uteru	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
reported	VBN	reported	reported	report	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
risk	NN	risk	risk	risk	N	O
among	IN	among	among	among	N	O
unopposed	JJ	unopposed	unopposed	unoppos	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	B-DrugClass
users	NNS	users	user	user	N	O
is	VBZ	is	is	is	N	O
about	RB	about	about	about	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
12	CD	12	12	12	N	O
times	NNS	times	time	time	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
users	NNS	users	user	user	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
appears	VBZ	appears	appears	appear	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
on	IN	on	on	on	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
studies	NNS	studies	study	studi	N	O
show	VBP	show	show	show	N	O
no	DT	no	no	no	N	O
significant	JJ	significant	significant	signific	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
for	IN	for	for	for	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
greatest	JJS	greatest	greatest	greatest	N	O
risk	NN	risk	risk	risk	N	O
appears	VBZ	appears	appears	appear	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
increased	JJ	increased	increased	increas	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
15	CD	15	15	15	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
for	IN	for	for	for	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
persist	VB	persist	persist	persist	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
8	CD	8	8	8	N	O
to	TO	to	to	to	N	O
15	CD	15	15	15	N	O
years	NNS	years	year	year	N	O
after	IN	after	after	after	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

DUAVEE	NNP	duavee	duavee	duave	N	O
contains	VBZ	contains	contains	contain	N	O
an	DT	an	an	an	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
agonist	NN	agonist	agonist	agonist	N	O
antagonist	NN	antagonist	antagonist	antagonist	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
component	NN	component	component	compon	N	O
reduces	VBZ	reduces	reduces	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	O
hyperplasia	NN	hyperplasia	hyperplasia	hyperplasia	Y	O
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
conjugated	JJ	conjugated	conjugated	conjug	N	O
estrogens	JJ	estrogens	estrogen	estrogen	N	O
component	NN	component	component	compon	N	O
.	.	.	.	.	N	O

Endometrial	JJ	endometrial	endometrial	endometri	N	O
hyperplasia	NN	hyperplasia	hyperplasia	hyperplasia	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
precursor	NN	precursor	precursor	precursor	N	O
to	TO	to	to	to	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
additional	JJ	additional	additional	addit	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
as	IN	as	a	as	N	O
this	DT	this	this	thi	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	O
hyperplasia	NN	hyperplasia	hyperplasia	hyperplasia	Y	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
surveillance	NN	surveillance	surveillance	surveil	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
.	.	.	.	.	N	O

Adequate	NNP	adequate	adequate	adequ	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
measures	NNS	measures	measure	measur	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
directed	VBD	directed	directed	direct	N	O
or	CC	or	or	or	N	O
random	JJ	random	random	random	N	O
endometrial	JJ	endometrial	endometrial	endometri	N	O
sampling	NN	sampling	sampling	sampl	N	O
when	WRB	when	when	when	N	O
indicated	VBN	indicated	indicated	indic	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
undertaken	VBN	undertaken	undertaken	undertaken	N	O
to	TO	to	to	to	N	O
rule	VB	rule	rule	rule	N	O
out	RP	out	out	out	N	O
malignancy	NN	malignancy	malignancy	malign	N	O
in	IN	in	in	in	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
undiagnosed	JJ	undiagnosed	undiagnosed	undiagnos	N	O
persistent	NN	persistent	persistent	persist	N	O
or	CC	or	or	or	N	O
recurring	VBG	recurring	recurring	recur	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
genital	JJ	genital	genital	genit	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

Breast	NNP	breast	breast	breast	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
important	JJ	important	important	import	N	O
randomized	VBN	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
providing	VBG	providing	providing	provid	N	O
information	NN	information	information	inform	N	O
about	IN	about	about	about	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
in	IN	in	in	in	N	O
estrogen	JJ	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	NN	alone	alone	alon	N	O
users	NNS	users	user	user	N	O
is	VBZ	is	is	is	N	O
the	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
substudy	NN	substudy	substudy	substudi	N	O
of	IN	of	of	of	N	O
daily	JJ	daily	daily	daili	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WHI	NNP	whi	whi	whi	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
substudy	NN	substudy	substudy	substudi	N	O
,	,	,	,	,	N	O
after	IN	after	after	after	N	O
an	DT	an	an	an	N	O
average	JJ	average	average	averag	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
7.1	CD	7.1	7.1	7.1	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
daily	RB	daily	daily	daili	N	O
conjugated	VBN	conjugated	conjugated	conjug	N	B-DrugClass
estrogen	NN	estrogen	estrogen	estrogen	Y	I-DrugClass
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	NN	alone	alone	alon	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
breast	NN	breast	breast	breast	N	I-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
(	(	(	(	(	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
[	NNP	[	[	[	N	O
RR	NNP	rr	rr	rr	N	O
]	NNP	]	]	]	N	O
0.80	CD	0.80	0.80	0.80	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	NN	alone	alone	alon	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
mammograms	NNS	mammograms	mammogram	mammogram	N	O
requiring	VBG	requiring	requiring	requir	N	O
further	JJ	further	further	further	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
women	NNS	women	woman	women	N	O
should	MD	should	should	should	N	O
receive	VB	receive	receive	receiv	N	O
yearly	RB	yearly	yearly	yearli	N	O
breast	JJ	breast	breast	breast	N	O
examinations	NNS	examinations	examination	examin	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
and	CC	and	and	and	N	O
perform	VB	perform	perform	perform	N	O
monthly	JJ	monthly	monthly	monthli	N	O
breast	NN	breast	breast	breast	N	O
self	PRP	self	self	self	N	O
-	:	-	-	-	N	O
examinations	NNS	examinations	examination	examin	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
mammography	NN	mammography	mammography	mammographi	N	O
examinations	NNS	examinations	examination	examin	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
scheduled	VBN	scheduled	scheduled	schedul	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
patient	JJ	patient	patient	patient	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
prior	JJ	prior	prior	prior	N	O
mammogram	NN	mammogram	mammogram	mammogram	Y	O
results	NNS	results	result	result	N	O
.	.	.	.	.	N	O

Ovarian	JJ	ovarian	ovarian	ovarian	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
epidemiological	JJ	epidemiological	epidemiological	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	B-DrugClass
-	:	-	-	-	N	O
only	RB	only	only	onli	N	O
products	NNS	products	product	product	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
particular	JJ	particular	particular	particular	N	O
for	IN	for	for	for	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
ovarian	JJ	ovarian	ovarian	ovarian	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
consistent	JJ	consistent	consistent	consist	N	O
across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
epidemiologic	JJ	epidemiologic	epidemiologic	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
some	DT	some	some	some	N	O
report	NN	report	report	report	N	O
no	DT	no	no	no	N	O
association	NN	association	association	associ	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
ovarian	JJ	ovarian	ovarian	ovarian	N	O
cancer	NN	cancer	cancer	cancer	Y	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Probable	JJ	probable	probable	probabl	N	O
Dementia	NN	dementia	dementia	dementia	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
WHIMS	NNP	whims	whim	whim	N	O
estrogen	SYM	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
ancillary	JJ	ancillary	ancillary	ancillari	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
WHI	NNP	whi	whi	whi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
947	CD	947	947	947	N	O
hysterectomized	VBD	hysterectomized	hysterectomized	hysterectom	N	O
women	NNS	women	woman	women	N	O
65	CD	65	65	65	N	O
to	TO	to	to	to	N	O
79	CD	79	79	79	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
daily	VB	daily	daily	daili	N	O
CE	NNP	ce	ce	ce	N	O
(	(	(	(	(	N	O
0.625	CD	0.625	0.625	0.625	N	O
mg	RB	mg	mg	mg	N	O
)-	JJ	)-	)-	)-	N	O
alone	RB	alone	alone	alon	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
an	DT	an	an	an	N	O
average	JJ	average	average	averag	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
5.2	CD	5.2	5.2	5.2	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
28	CD	28	28	28	N	O
women	NNS	women	woman	women	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
19	CD	19	19	19	N	O
women	NNS	women	woman	women	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
were	VBD	were	were	were	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
with	IN	with	with	with	N	O
probable	JJ	probable	probable	probabl	N	O
dementia	NN	dementia	dementia	dementia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
probable	JJ	probable	probable	probabl	N	O
dementia	NN	dementia	dementia	dementia	Y	B-AdverseReaction
for	IN	for	for	for	N	O
CE	NNP	ce	ce	ce	N	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
1.49	CD	1.49	1.49	1.49	N	O
(	(	(	(	(	N	O
95	CD	95	95	95	N	O
percent	NN	percent	percent	percent	N	O
CI	NNP	ci	ci	ci	N	O
,	,	,	,	,	N	O
0.83	CD	0.83	0.83	0.83	N	O
-	:	-	-	-	N	O
2.66	CD	2.66	2.66	2.66	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
probable	JJ	probable	probable	probabl	N	O
dementia	NN	dementia	dementia	dementia	Y	B-AdverseReaction
for	IN	for	for	for	N	O
CE	NNP	ce	ce	ce	N	B-DrugClass
-	:	-	-	-	N	O
alone	RB	alone	alone	alon	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
37	CD	37	37	37	N	O
versus	NN	versus	versus	versu	N	O
25	CD	25	25	25	N	O
cases	NNS	cases	case	case	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
women	NNS	women	woman	women	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.6	CD	14.6	14.6	14.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Gallbladder	NNP	gallbladder	gallbladder	gallbladd	N	O
Disease	NNP	disease	disease	diseas	N	O

A	DT	a	a	a	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
fold	JJ	fold	fold	fold	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
gallbladder	NN	gallbladder	gallbladder	gallbladd	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
in	IN	in	in	in	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	O
women	NNS	women	woman	women	N	O
receiving	VBG	receiving	receiving	receiv	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Visual	JJ	visual	visual	visual	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

Retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
vascular	JJ	vascular	vascular	vascular	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
medication	NN	medication	medication	medic	N	O
pending	VBG	pending	pending	pend	N	O
examination	NN	examination	examination	examin	N	O
if	IN	if	if	if	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
sudden	JJ	sudden	sudden	sudden	N	O
partial	JJ	partial	partial	partial	N	O
or	CC	or	or	or	N	O
complete	JJ	complete	complete	complet	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
sudden	JJ	sudden	sudden	sudden	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
proptosis	NN	proptosis	proptosis	proptosi	Y	O
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
migraine	NN	migraine	migraine	migrain	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
examination	NN	examination	examination	examin	N	O
reveals	NNS	reveals	reveals	reveal	N	O
papilledema	VBP	papilledema	papilledema	papilledema	Y	O
or	CC	or	or	or	N	O
retinal	JJ	retinal	retinal	retin	N	O
vascular	JJ	vascular	vascular	vascular	N	O
lesions	NNS	lesions	lesion	lesion	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Elevated	VBD	elevated	elevated	elev	N	O
Blood	NNP	blood	blood	blood	N	O
Pressure	NN	pressure	pressure	pressur	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
small	JJ	small	small	small	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
case	NN	case	case	case	N	O
reports	NNS	reports	report	report	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
receiving	VBG	receiving	receiving	receiv	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
,	,	,	,	,	N	O
substantial	JJ	substantial	substantial	substanti	N	B-Severity
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
idiosyncratic	JJ	idiosyncratic	idiosyncratic	idiosyncrat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
generalized	JJ	generalized	generalized	gener	N	O
effect	NN	effect	effect	effect	N	B-AdverseReaction
of	IN	of	of	of	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
on	IN	on	on	on	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	B-Negation
seen	VBN	seen	seen	seen	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	O

In	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
plasma	NN	plasma	plasma	plasma	N	I-AdverseReaction
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	I-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
pancreatitis	VB	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
if	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Impairment	NNP	impairment	impairment	impair	N	O
and	CC	and	and	and	N	O
Past	NNP	past	past	past	N	O
History	NNP	history	history	histori	N	O
of	IN	of	of	of	N	O
Cholestatic	NNP	cholestatic	cholestatic	cholestat	N	O
Jaundice	NNP	jaundice	jaundice	jaundic	Y	O

DUAVEE	NNP	duavee	duavee	duave	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
or	CC	or	or	or	N	O
past	JJ	past	past	past	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
cholestatic	JJ	cholestatic	cholestatic	cholestat	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
.	.	.	.	.	N	O

Estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
poorly	RB	poorly	poorly	poorli	N	O
metabolized	VBN	metabolized	metabolized	metabol	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

On	IN	on	on	on	N	O
average	NN	average	average	averag	N	O
,	,	,	,	,	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
bazedoxifene	NN	bazedoxifene	bazedoxifene	bazedoxifen	N	O
alone	RB	alone	alone	alon	N	O
showed	VBD	showed	showed	show	N	O
a	DT	a	a	a	N	O
4.3	CD	4.3	4.3	4.3	N	O
-	:	-	-	-	N	O
fold	JJ	fold	fold	fold	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
overall	JJ	overall	overall	overal	N	O
exposures	NNS	exposures	exposure	exposur	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
controls	NNS	controls	control	control	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.7	CD	8.7	8.7	8.7	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
cholestatic	JJ	cholestatic	cholestatic	cholestat	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
past	JJ	past	past	past	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
use	NN	use	use	use	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
,	,	,	,	,	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	O

Estrogen	NNP	estrogen	estrogen	estrogen	Y	O
administration	NN	administration	administration	administr	N	O
leads	VBZ	leads	lead	lead	N	O
to	TO	to	to	to	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
thyroid	JJ	thyroid	thyroid	thyroid	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
binding	NN	binding	binding	bind	N	I-AdverseReaction
globulin	NN	globulin	globulin	globulin	Y	I-AdverseReaction
(	(	(	(	(	N	O
TBG	NNP	tbg	tbg	tbg	Y	I-AdverseReaction
)	)	)	)	)	N	O
levels	NNS	levels	level	level	N	I-AdverseReaction
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
can	MD	can	can	can	N	O
compensate	VB	compensate	compensate	compens	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
TBG	NN	tbg	tbg	tbg	Y	I-AdverseReaction
by	IN	by	by	by	N	O
making	VBG	making	making	make	N	O
more	JJR	more	more	more	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
,	,	,	,	,	N	O
thus	RB	thus	thus	thu	N	O
maintaining	VBG	maintaining	maintaining	maintain	N	O
free	JJ	free	free	free	N	O
T4	NNP	t4	t4	t4	Y	O
and	CC	and	and	and	N	O
T3	NNP	t3	t3	t3	Y	O
serum	VBP	serum	serum	serum	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
.	.	.	.	.	N	O

Women	NNP	women	woman	women	N	O
dependent	NN	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
also	RB	also	also	also	N	O
receiving	VBG	receiving	receiving	receiv	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
increased	JJ	increased	increased	increas	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
women	NNS	women	woman	women	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
their	PRP$	their	their	their	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
monitored	VBD	monitored	monitored	monitor	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
to	TO	to	to	to	N	O
maintain	VB	maintain	maintain	maintain	N	O
their	PRP$	their	their	their	N	O
free	JJ	free	free	free	N	O
thyroid	NN	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
acceptable	JJ	acceptable	acceptable	accept	N	O
range	NN	range	range	rang	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Fluid	NNP	fluid	fluid	fluid	N	O
Retention	NN	retention	retention	retent	N	O

Estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
some	DT	some	some	some	N	O
degree	NN	degree	degree	degre	N	O
of	IN	of	of	of	N	O
fluid	NN	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
might	MD	might	might	might	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
this	DT	this	this	thi	N	O
factor	NN	factor	factor	factor	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
or	CC	or	or	or	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
warrant	VBP	warrant	warrant	warrant	N	O
careful	JJ	careful	careful	care	N	O
observation	NN	observation	observation	observ	N	O
when	WRB	when	when	when	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
are	VBP	are	are	are	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	O

Estrogen	NNP	estrogen	estrogen	estrogen	Y	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
hypoparathyroidism	NN	hypoparathyroidism	hypoparathyroidism	hypoparathyroid	Y	O
as	IN	as	a	as	N	O
estrogen	NN	estrogen	estrogen	estrogen	Y	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Hereditary	NNP	hereditary	hereditary	hereditari	N	O
Angioedema	NNP	angioedema	angioedema	angioedema	Y	O

Exogenous	JJ	exogenous	exogenous	exogen	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	B-Factor
exacerbate	VB	exacerbate	exacerbate	exacerb	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	I-AdverseReaction
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
.	.	.	.	.	N	O

5.14	CD	5.14	5.14	5.14	N	O
Exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
of	IN	of	of	of	N	O
Other	JJ	other	other	other	N	O
Conditions	NNS	conditions	condition	condit	N	O

Estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
an	DT	an	an	an	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
mellitus	NN	mellitus	mellitus	mellitu	N	O
,	,	,	,	,	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
,	,	,	,	,	N	O
migraine	NN	migraine	migraine	migrain	Y	O
or	CC	or	or	or	N	O
porphyria	NN	porphyria	porphyria	porphyria	Y	O
,	,	,	,	,	N	O
systemic	JJ	systemic	systemic	system	N	O
lupus	NN	lupus	lupus	lupu	N	O
erythematosus	NN	erythematosus	erythematosus	erythematosu	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
hemangiomas	NN	hemangiomas	hemangioma	hemangioma	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
conditions	NNS	conditions	condition	condit	N	O
.	.	.	.	.	N	O

5.15	CD	5.15	5.15	5.15	N	O
Premenopausal	NNP	premenopausal	premenopausal	premenopaus	N	O
Women	NNP	women	woman	women	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
indication	NN	indication	indication	indic	N	O
for	IN	for	for	for	N	O
premenopausal	NN	premenopausal	premenopausal	premenopaus	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
DUAVEE	NNP	duavee	duavee	duave	N	O
in	IN	in	in	in	N	O
premenopausal	JJ	premenopausal	premenopausal	premenopaus	N	O
women	NNS	women	woman	women	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
its	PRP$	its	it	it	N	O
use	NN	use	use	use	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

5.16	CD	5.16	5.16	5.16	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O

Serum	NNP	serum	serum	serum	N	O
follicle	NN	follicle	follicle	follicl	N	O
stimulating	VBG	stimulating	stimulating	stimul	N	O
hormone	NN	hormone	hormone	hormon	N	O
(	(	(	(	(	N	O
FSH	NNP	fsh	fsh	fsh	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
estradiol	JJ	estradiol	estradiol	estradiol	Y	O
levels	NNS	levels	level	level	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
useful	JJ	useful	useful	use	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
vasomotor	NN	vasomotor	vasomotor	vasomotor	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

5.17	CD	5.17	5.17	5.17	N	O
Drug	NNP	drug	drug	drug	N	O
-	:	-	-	-	N	O
Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Test	NNP	test	test	test	N	O
Interactions	NNS	interactions	interaction	interact	N	O

Accelerated	NNP	accelerated	accelerated	acceler	N	B-AdverseReaction
prothrombin	NN	prothrombin	prothrombin	prothrombin	Y	I-AdverseReaction
time	NN	time	time	time	N	I-AdverseReaction
,	,	,	,	,	N	O
partial	JJ	partial	partial	partial	N	I-AdverseReaction
thromboplastin	NN	thromboplastin	thromboplastin	thromboplastin	Y	I-AdverseReaction
time	NN	time	time	time	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
platelet	VB	platelet	platelet	platelet	N	I-AdverseReaction
aggregation	NN	aggregation	aggregation	aggreg	N	I-AdverseReaction
time	NN	time	time	time	N	I-AdverseReaction
;	:	;	;	;	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
platelet	NN	platelet	platelet	platelet	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
;	:	;	;	;	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
factors	NNS	factors	factor	factor	N	I-AdverseReaction
II	NNP	ii	ii	ii	N	I-AdverseReaction
,	,	,	,	,	N	O
VII	NNP	vii	vii	vii	N	I-AdverseReaction
antigen	NN	antigen	antigen	antigen	N	I-AdverseReaction
,	,	,	,	,	N	O
VIII	NNP	viii	viii	viii	N	I-AdverseReaction
antigen	NN	antigen	antigen	antigen	N	I-AdverseReaction
,	,	,	,	,	N	O
VIII	NNP	viii	viii	viii	N	I-AdverseReaction
coagulant	NN	coagulant	coagulant	coagul	N	I-AdverseReaction
activity	NN	activity	activity	activ	N	I-AdverseReaction
,	,	,	,	,	N	O
IX	NNP	ix	ix	ix	N	I-AdverseReaction
,	,	,	,	,	N	O
X	NNP	x	x	x	N	I-AdverseReaction
,	,	,	,	,	N	O
XII	NNP	xii	xii	xii	N	I-AdverseReaction
,	,	,	,	,	N	O
VII	NNP	vii	vii	vii	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
X	NN	x	x	x	N	I-AdverseReaction
complex	NN	complex	complex	complex	N	I-AdverseReaction
,	,	,	,	,	N	O
II	NNP	ii	ii	ii	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
VII	NNP	vii	vii	vii	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
X	NN	x	x	x	N	I-AdverseReaction
complex	NN	complex	complex	complex	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
beta	SYM	beta	beta	beta	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
thromboglobulin	NN	thromboglobulin	thromboglobulin	thromboglobulin	N	I-AdverseReaction
;	:	;	;	;	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
antifactor	NN	antifactor	antifactor	antifactor	N	I-AdverseReaction
Xa	NNP	xa	xa	xa	N	I-AdverseReaction
and	CC	and	and	and	N	O
antithrombin	JJ	antithrombin	antithrombin	antithrombin	N	I-AdverseReaction
III	NNP	iii	iii	iii	N	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
antithrombin	JJ	antithrombin	antithrombin	antithrombin	N	I-AdverseReaction
III	NNP	iii	iii	iii	N	I-AdverseReaction
activity	NN	activity	activity	activ	N	I-AdverseReaction
;	:	;	;	;	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
fibrinogen	NN	fibrinogen	fibrinogen	fibrinogen	Y	I-AdverseReaction
and	CC	and	and	and	N	O
fibrinogen	NN	fibrinogen	fibrinogen	fibrinogen	Y	I-AdverseReaction
activity	NN	activity	activity	activ	N	I-AdverseReaction
;	:	;	;	;	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
plasminogen	NN	plasminogen	plasminogen	plasminogen	Y	I-AdverseReaction
antigen	NN	antigen	antigen	antigen	N	I-AdverseReaction
and	CC	and	and	and	N	O
activity	NN	activity	activity	activ	N	I-AdverseReaction
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
thyroid	JJ	thyroid	thyroid	thyroid	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
binding	NN	binding	binding	bind	N	I-AdverseReaction
globulin	NN	globulin	globulin	globulin	Y	I-AdverseReaction
(	(	(	(	(	N	O
TBG	NNP	tbg	tbg	tbg	Y	I-AdverseReaction
)	)	)	)	)	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
circulating	VBG	circulating	circulating	circul	N	I-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
measured	VBN	measured	measured	measur	N	O
by	IN	by	by	by	N	O
protein	NN	protein	protein	protein	Y	O
-	:	-	-	-	N	O
bound	NN	bound	bound	bound	N	O
iodine	NN	iodine	iodine	iodin	N	O
(	(	(	(	(	N	O
PBI	NNP	pbi	pbi	pbi	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
T4	NNP	t4	t4	t4	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
(	(	(	(	(	N	O
by	IN	by	by	by	N	O
column	NN	column	column	column	N	O
or	CC	or	or	or	N	O
by	IN	by	by	by	N	O
radioimmunoassay	NN	radioimmunoassay	radioimmunoassay	radioimmunoassay	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
T3	NNP	t3	t3	t3	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
by	IN	by	by	by	N	O
radioimmunoassay	NN	radioimmunoassay	radioimmunoassay	radioimmunoassay	N	O
.	.	.	.	.	N	O

T3	NNP	t3	t3	t3	Y	B-AdverseReaction
resin	NN	resin	resin	resin	N	I-AdverseReaction
uptake	NN	uptake	uptake	uptak	N	I-AdverseReaction
is	VBZ	is	is	is	N	O
decreased	VBN	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
reflecting	VBG	reflecting	reflecting	reflect	N	O
the	DT	the	the	the	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
TBG	NNP	tbg	tbg	tbg	Y	I-AdverseReaction
.	.	.	.	.	N	O

Free	JJ	free	free	free	N	O
T4	NNP	t4	t4	t4	Y	O
and	CC	and	and	and	N	O
free	JJ	free	free	free	N	O
T3	NNP	t3	t3	t3	Y	O
concentrations	NNS	concentrations	concentration	concentr	N	O
are	VBP	are	are	are	N	O
unaltered	JJ	unaltered	unaltered	unalt	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
on	IN	on	on	on	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
higher	JJR	higher	higher	higher	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
binding	VBG	binding	binding	bind	N	O
proteins	NNS	proteins	protein	protein	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
in	IN	in	in	in	N	O
serum	NN	serum	serum	serum	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
corticosteroid	VB	corticosteroid	corticosteroid	corticosteroid	N	I-AdverseReaction
binding	VBG	binding	binding	bind	N	I-AdverseReaction
globulin	NN	globulin	globulin	globulin	Y	I-AdverseReaction
(	(	(	(	(	N	O
CBG	NNP	cbg	cbg	cbg	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
sex	NN	sex	sex	sex	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
binding	NN	binding	binding	bind	N	I-AdverseReaction
globulin	NN	globulin	globulin	globulin	Y	I-AdverseReaction
(	(	(	(	(	N	O
SHBG	NNP	shbg	shbg	shbg	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
circulating	NN	circulating	circulating	circul	N	I-AdverseReaction
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	I-AdverseReaction
and	CC	and	and	and	N	O
sex	NN	sex	sex	sex	N	I-AdverseReaction
steroids	NNS	steroids	steroid	steroid	N	I-AdverseReaction
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Free	JJ	free	free	free	N	B-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
testosterone	NN	testosterone	testosterone	testosteron	Y	B-AdverseReaction
and	CC	and	and	and	N	O
estradiol	NN	estradiol	estradiol	estradiol	Y	B-AdverseReaction
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
decreased	VBN	decreased	decreased	decreas	N	I-AdverseReaction
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
plasma	JJ	plasma	plasma	plasma	N	B-AdverseReaction
proteins	NNS	proteins	protein	protein	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
increased	VBN	increased	increased	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
angiotensinogen	JJ	angiotensinogen	angiotensinogen	angiotensinogen	N	I-AdverseReaction
renin	NN	renin	renin	renin	Y	I-AdverseReaction
substrate	NN	substrate	substrate	substrat	N	I-AdverseReaction
,	,	,	,	,	N	O
alpha	SYM	alpha	alpha	alpha	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
antitrypsin	NN	antitrypsin	antitrypsin	antitrypsin	N	I-AdverseReaction
,	,	,	,	,	N	O
ceruloplasmin	NN	ceruloplasmin	ceruloplasmin	ceruloplasmin	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
plasma	NN	plasma	plasma	plasma	N	I-AdverseReaction
high	JJ	high	high	high	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
lipoprotein	NN	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
(	(	(	(	(	N	O
HDL	NNP	hdl	hdl	hdl	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
HDL2	NNP	hdl2	hdl2	hdl2	N	I-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
subfraction	NN	subfraction	subfraction	subfract	N	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
,	,	,	,	,	N	O
reduced	VBD	reduced	reduced	reduc	N	B-AdverseReaction
low	JJ	low	low	low	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
lipoprotein	NN	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
)	)	)	)	)	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
triglyceride	NN	triglyceride	triglyceride	triglycerid	N	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
.	.	.	.	.	N	O

Impaired	NNP	impaired	impaired	impair	N	B-AdverseReaction
glucose	VBD	glucose	glucose	glucos	Y	I-AdverseReaction
tolerance	NN	tolerance	tolerance	toler	N	I-AdverseReaction
.	.	.	.	.	N	O

